Duodenoscope Infection Lawsuit

Since 2010, outbreaks of antibiotic-resistant infections traced to contaminated duodenoscopes have resulted in prolonged hospitalizations and permanent organ damage. The complex duodenoscope elevator design has created challenges for sterilization, often leaving harmful bacteria behind. Olympus, which controls roughly 85% of the U.S. duodenoscope market, has been the primary defendant in Olympus scope lawsuit filings, though Pentax and Fujifilm also face claims.

We understand the profound impact these infections have on patients and families. Victims face mounting medical bills, lost income, and long-term complications. Our legal team is dedicated to holding manufacturers accountable for design defects that may have put countless patients at unnecessary risk.

A duodenoscope infection lawsuit seeks compensation for patients contracting infections from contaminated scopes during ERCP procedures. These legal actions allege that manufacturers designed instruments making sterilization difficult, exposing patients to dangerous bacteria. As product liability lawyers handling defective medical devices, we know some key facts include:

• Between 500,000 and 700,000 ERCPs are performed annually in the United States.
• The elevator mechanism design is central to contamination risks.
• Risk of patient-to-patient bacterial transmission.
• Documented infection rates linked to these devices.

Why These Scopes Cannot Be Adequately Cleaned

The duodenoscope elevator is a tiny mechanical lever at the tip of the scope that lets physicians guide instruments during ERCP procedures. Without it, the procedure would not be possible. But this same component has become the source of the contamination crisis driving these lawsuits.

The elevator channel is not a smooth, open cavity. It contains microscopic gaps between the lever and its housing, along with O-rings, seals, and joints that trap fluid and biological debris. After a procedure, this area is contaminated with bile, blood, pancreatic fluid, and tissue. The geometry of the channel makes it physically impossible for brushes, detergents, or high-level disinfection chemicals to reach every contaminated surface.

Bacteria that survive cleaning do not simply sit and wait to be wiped away. They form biofilms, or structured colonies that adhere to surfaces and secrete a protective matrix. Once a biofilm establishes itself inside the elevator channel, standard chemical disinfection cannot penetrate it. The contamination persists, and the next patient is exposed to whatever organisms the previous patient was carrying. 

Safer Alternatives Were Available

One of the strongest arguments in newer duodenoscope cases is that manufacturers were not stuck with a single engineering option. Fully disposable duodenoscopes, used once and discarded, were already on the market by the time many of the recent procedures took place. These devices can eliminate cross-contamination entirely. Under product liability law, a viable safer alternative design may strengthen design defect claims, particularly against manufacturers like Olympus that continued selling reusable scopes despite years of contamination data.

The bacteria associated with contaminated duodenoscopes are particularly dangerous. They include:

• E. coli
• Pseudomonas aeruginosa
• Klebsiella pneumoniae
• Vancomycin-resistant Enterococcus (VRE)
• Carbapenem-resistant Enterobacteriaceae (CRE), with mortality rates approaching 50% when the infection enters the bloodstream

Signs of infection after ERCP may appear days to weeks later. Symptoms include:

• Persistent fever and chills
• Severe abdominal pain
• Rapid heartbeat or low blood pressure
• Confusion or disorientation

In many cases, hospital negligence in following cleaning and sterilization protocols may also play a role.

What These Infections Mean for Patients

Statistics do not capture what it is like to contract one of these infections after a routine medical procedure. Patients who entered the hospital for routine evaluations have left with permanent organ damage, lifelong dialysis, and drug-resistant organisms that may colonize their bodies for years.

Documented outcomes include weeks or months in intensive care, multiple surgeries to control the infection, septic shock, kidney failure, and the exhaustion of every available antibiotic. Some patients survive but never recover their previous quality of life. Others do not survive at all. This is what the duodenoscope litigation is about. Real patients and families whose lives were altered.

You may qualify if you underwent an ERCP and suffered an infection. Criteria include:

• The procedure involved an Olympus, Pentax, or Fujifilm duodenoscope documented in your medical records.
• An infection developed within roughly 90 days of the procedure, particularly involving drug-resistant bacteria like CRE, Pseudomonas, Klebsiella, or VRE.
• The infection required hospitalization, IV antibiotics, ICU admission, surgery, or caused permanent harm.
• Hospital exposure notifications or culture results document the bacterial strain.

The Olympus scope lawsuit history is not a single event but a 14-year pattern of regulatory violations, concealed warnings, and continued sales of devices the company knew could not be reliably sterilized. This documented timeline strengthens current claims against Olympus and undercuts the company’s standard defenses.

• June 2012: An independent investigator hired by Olympus and a Netherlands hospital concludes that the TJF-Q180V duodenoscope’s design can allow blood and tissue to become trapped, spreading bacteria between patients. The expert calls on Olympus to conduct a worldwide investigation and recall scopes if similar problems appear elsewhere.
• January 2013: Olympus sends an “Important Safety Advice” notice to European hospitals warning that contaminated TJF-Q180V duodenoscopes have been linked to patient infections, even when cleaning instructions are followed. U.S. hospitals are not notified.
• August 2014: Olympus issues a second European field safety notice addressing “prevention of cross-infection among patients.” U.S. hospitals are still not warned.
• February 2015: After the UCLA Ronald Reagan Medical Center outbreak becomes public, Olympus finally alerts American hospitals. Senate investigators later estimate that approximately 200 additional patients may have been infected at UCLA alone during the two-year warning gap, with many more potentially exposed at hospitals nationwide.
• March 2016: Olympus pays $646 million to resolve unrelated kickback and Foreign Corrupt Practices Act charges, the largest amount ever paid by a medical device company under the Anti-Kickback Statute. The settlement is unrelated to the duodenoscope contamination crisis but establishes a broader pattern of regulatory misconduct.
• December 10, 2018: Olympus Medical Systems Corporation pleads guilty in federal court in Newark, New Jersey, to three counts of distributing misbranded medical devices, paying an $80 million fine and forfeiting an additional $5 million for a total of $85 million in penalties. Former senior executive Hisao Yabe also pleads guilty.
• May 2025: Olympus rewrites Section 5.9 of the TJF-Q190V, TJF-Q290V, and TJF-Q170V reprocessing manual, eliminating the previously validated 24-hour presoak option after post-market surveillance shows that delaying manual cleaning beyond one hour produced more microbial contamination, not less. In Olympus’s own words, the cleaning instructions hospitals had been following on Olympus’s representation that they were validated were producing worse outcomes in real-world use.
• June 24, 2025: The FDA issues Import Alert 89-04, blocking 58 Olympus product models manufactured at the Aizu facility in Fukushima, Japan. While those models cover bronchoscopes, laparoscopes, ureterorenoscopes, and automated endoscope reprocessors rather than duodenoscopes, the action documents systemic quality system violations at an Olympus facility already on its third FDA warning letter.
• October 17, 2025: Olympus issues a worldwide Urgent Field Safety Notice for its TJF-Q190V, TJF-Q290V, and TJF-Q170V duodenoscopes, explicitly acknowledging the notice was prompted by ongoing “positive cultures and infections.” The company confirms 2 reports of death and 5 reports of serious injury related to infections involving these scopes from 2024 to October 2025. Olympus also introduces a new requirement that hospitals visually inspect the distal tip under 10x magnification because, in the company’s own words, naked-eye inspection cannot reliably detect the irregularities and damage that can trap bacteria. The legal implication is direct: if 10x magnification is required for safety now, every naked-eye inspection performed under Olympus’s prior instructions over the last decade was, by Olympus’s own current standard, inadequate.
• March 2026: Health Canada and the FDA issue recalls covering Olympus MAJ-1443 and MAJ-1444 valves used with the OER-Pro endoscope reprocessor after the components are found to be incompatible with the cleaning system, potentially compromising disinfection and increasing patient-to-patient contamination risk.

These regulatory actions confirm what plaintiffs have argued for over a decade: Olympus never truly resolved the fundamental design and reprocessing problems that allow bacteria to survive between patients. The pattern is still active in 2026, which means new claims continue to emerge and statute-of-limitations clocks for many patients have not yet expired.

Because duodenoscope cases often involve large groups of affected patients, our class action lawyers are equipped to pursue mass tort claims when appropriate.

Compensation types include:

• Economic Damages:
  • Medical expenses (potentially exceeding $500,000)
  • Lost wages and future earnings
  • Long-term and lifetime care costs
• Non-Economic Damages:
  • Pain and suffering
  • Psychological impact
  • Quality of life changes

In 2017, a Washington state jury delivered a $6.6 million verdict against Olympus in the first U.S. trial over duodenoscope-related superbug infections. The case was filed by Theresa Bigler and her four children after her 57-year-old husband, Richard Bigler, died in August 2013 from a carbapenem-resistant Enterobacteriaceae infection traced to a contaminated Olympus TJF-Q180V duodenoscope used during his treatment at Virginia Mason Medical Center. Virginia Mason later joined the lawsuit as a co-plaintiff after the same scope outbreak at the Seattle hospital was linked to 39 patient infections and at least 18 deaths. Following an eight-week trial, the jury found that Olympus failed to provide adequate warnings and cleaning instructions, ordering $1 million of the $6.6 million verdict diverted to the Bigler family. The case established a foundation that strengthens every Olympus scope lawsuit filed since, particularly newer cases involving the TJF-Q190V series and the 2025 admissions about insufficient reprocessing. 

Most individual patient and family settlements have been resolved confidentially, with amounts believed to be substantial given the severity of injuries involved. Factors influencing settlements involve the severity of infections, the cost of treatments, evidence of corporate misconduct, and punitive damages for egregious conduct.

For families who have lost a loved one to a CRE or other drug-resistant infection, our wrongful death lawyers may be able to pursue additional damages, including funeral expenses, loss of companionship, and loss of future earnings, on your behalf.

At Gordon & Partners Law Firm, we use a strategic, detail-oriented approach to medical device cases. We may collaborate with medical experts to analyze device flaws truly. Because many duodenoscope infections occur in healthcare settings, our experience handling medical malpractice claims allows us to investigate both manufacturer and hospital liability if necessary. Our contingency fee structure also ensures individuals get access to legal representation regardless of their financial state.